Zha, Lei, Zhang, Dayan, Pan, Lingling, Ren, Zhichu, Li, Xiang, Zou, Yi, Li, Shirong, Luo, Shuangqi, Yang, Gang and Tefsen, Boris 
ORCID: 0000-0001-6668-217X
(2021)
Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to <i>Stenotrophomonas maltophilia</i>: A Multicenter Retrospective Cohort Study.
INFECTIOUS DISEASES AND THERAPY, 10 (4).
pp. 2415-2429.
|
PDF
Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia A Multicenter Retrospect.pdf - Open Access published version Download (488kB) | Preview |
Abstract
<h4>Introduction</h4>Tigecycline is a potential alternative to trimethoprim-sulfamethoxazole in treating Stenotrophomonas maltophilia infections due to its potent in vitro antimicrobial activity. Clinical evidence regarding the use of tigecycline in the treatment of S. maltophilia infections is scarce. In this study, we assessed the efficacy of tigecycline treating ventilator-associated pneumonia (VAP) due to S. maltophilia in comparison with fluoroquinolones.<h4>Methods</h4>This is a multicenter retrospective cohort study of patients admitted between January 2017 and December 2020 with the diagnosis of VAP caused by S. maltophilia receiving either tigecycline or fluoroquinolones as the definitive therapy ≥ 48 h. Clinical outcomes including 28-day mortality, clinical cure and microbiological cure were analyzed.<h4>Results</h4>Of 82 patients with S. maltophilia VAP included, 46 received tigecycline, and 36 received fluoroquinolones; 70.7% of patients had polymicrobial pneumonia, and the appropriate empiric therapy was applied to only 14.6% of patients. The overall 28-day mortality was 39%. Compared with patients receiving fluoroquinolones, tigecycline therapy resulted in worse clinical cure (32.6% vs. 63.9%, p = 0.009) and microbiological cure (28.6% vs. 59.1%, p = 0.045), while there was no statistical difference between 28-day mortality (47.8% vs. 27.8%, p = 0.105) in the two groups. Similar results were also shown in the inverse probability of treatment weighted univariable regression model and multivariable regression model.<h4>Conclusions</h4>The standard dose of tigecycline therapy was associated with a lower clinical and microbiological cure rate but not associated with an increased 28-day mortality in patients with S. maltophilia VAP compared with fluoroquinolones. Considering the unfavorable clinical outcomes, we therefore recommend against using the standard dose of tigecycline in treating S. maltophilia VAP unless new clinical evidence emerges.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Fluoroquinolones, Levofloxacin, Moxifloxacin, Multicenter retrospective cohort study, Stenotrophomonas maltophilia, Tigecycline, Ventilator-associated pneumonia |
| Divisions: | Faculty of Health and Life Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 06 Jul 2023 13:38 |
| Last Modified: | 17 Oct 2023 16:22 |
| DOI: | 10.1007/s40121-021-00516-5 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3171508 |
Dimensions
Dimensions
